Related Experiment Video
Updated: Mar 12, 2026
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
Development of an HTS-Compatible Assay for Discovery of Melanoma-Related Microphthalmia Transcription Factor
Jing Wang1,2, Pengfei Fang1,2, Peter Chase3,4
11 Department of Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, USA.
Abstract:
Microphthalmia transcription factor (MITF) is a master transcription factor expressed in melanocytes, essential for melanocyte survival, differentiation, and pigment formation, and is a key oncogenic factor in melanoma initiation, migration, and treatment resistance. Although identified as an important therapeutic target for melanoma, clinical inhibitors directly targeting the MITF protein are not available. Based on the functional state of MITF, we have designed an MITF dimerization-based AlphaScreen (MIDAS) assay that sensitively and specifically mirrors the dimerization of MITF in vitro. This assay is further exploited for identification of the MITF dimer disruptor for high-throughput screening. A pilot screen against a library of 1280 pharmacologically active compounds indicates that the MIDAS assay performance exhibits exceptional results with a Z' factor of 0.81 and a signal-to-background (S/B) ratio of 3.92 while identifying initial hit compounds that yield an ability to disrupt MITF-DNA interaction. The results presented demonstrate that the MIDAS assay is ready to screen large chemical libraries in order to discover novel modulators of MITF for potential melanoma treatment.
Insights
Researchers developed a new assay to screen for drugs that disrupt Microphthalmia Transcription Factor (MITF) dimerization, a key factor in melanoma. This assay is crucial for discovering novel melanoma treatments targeting MITF.
Area of Science:
- Molecular Biology
- Oncology
- Drug Discovery
Background:
- Microphthalmia transcription factor (MITF) is crucial for melanocyte function and a key driver in melanoma.
- MITF is a therapeutic target for melanoma, but direct inhibitors are lacking.
- MITF dimerization is a critical functional state relevant to its oncogenic activity.
Purpose of the Study:
- To design and validate a high-throughput screening assay for MITF modulators.
- To identify compounds that disrupt MITF dimerization.
- To establish a platform for discovering novel melanoma therapeutics targeting MITF.
Main Methods:
- Development of an AlphaScreen assay (MIDAS) to measure MITF dimerization in vitro.
- High-throughput screening of a 1280-compound library using the MIDAS assay.
- Evaluation of assay performance using Z' factor and signal-to-background ratio.
Main Results:
- The MIDAS assay demonstrated high performance with a Z' factor of 0.81 and S/B ratio of 3.92.
- The assay successfully identified initial hit compounds capable of disrupting MITF-DNA interaction.
- Pilot screening confirmed the assay's sensitivity and specificity for detecting MITF dimer disruptors.
Conclusions:
- The MIDAS assay is a validated tool for high-throughput screening of MITF modulators.
- This assay provides a promising platform for discovering novel therapeutic agents for melanoma.
- Targeting MITF dimerization represents a viable strategy for developing new melanoma treatments.
